Bisphosphonate‐associated osteonecrosis of the jaw. Knowledge and attitudes of dentists and dental students: a preliminary study

López‐Jornet, Pía; Camacho-Alonso, Fabio; Molina‐Miñano, Francisco; Gómez-García, Francisco

doi:10.1111/j.1365-2753.2009.01203.x

Cited by 40 publications

(34 citation statements)

References 23 publications

(65 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With the purpose of identifying which patients had a greater risk of BRONJ, it has been proposed the usefulness of determining serum CTX (telomere C-terminal of collagen 1), a biologic index to measure bone remodeling and bone resorption, pointing out that those patients who had taken oral BPs for more than 3 years and who had CTX below 150 pg/ml would be at greater risk of developing BRONJ during dental surgery (22,35). Kwon et al (36) correlated the staging of osteonecrosis with serum CTX in 18 osteoporotic patients receiving oral BPs treatment, the authors found a significant correlation between the disease severity and the risk assessment using serum CTX.…”

Section: Methodsmentioning

confidence: 99%

“…Lópes-Jornet et al (35), Migliorati et al (15) and Bauer et al (3) observed that in all groups only a minority knew adequate information concerning the use of BPs, suggesting that greater educational efforts should be made to promote knowledge of this pathology at both undergraduate and postgraduate levels, and that the majority of the patients receiving oral or IV BPs are not adequately informed about possible adverse effects of their BP therapy. Table 1 shows the most important topics related to AONJ.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Alendronate-associated osteonecrosis of the jaws: A review of the main topics

Fonseca

Santos‐Silva²,

Della-Coletta³

et al. 2014

Med Oral

View full text Add to dashboard Cite

Bisphosphonates is a group of inorganic pyrophosphates analogues that suppress bone resorption by inducing osteoclast inactivation, being frequently used for management of diseases affecting bone metabolism, bone metastases and bone tumors. However, since 2003 many cases describing the presence of necrotic bone exposures in the jaws have been described in patients receiving these drugs, what represent a significant complication of bisphosphonates treatment. The overall incidence of bisphosphonate-related osteonecrosis of the jaws is low, ranging from 0.7% to 12%, mainly observed in those patients receiving intravenously treatment. Osteonecrosis of the jaws associated to oral bisphosphonate, particularly alendronate, has also been reported by a number of authors. Considering that alendronate is one of the most used drugs worldwide, specially for treatment of osteoporosis, a better understanding of osteonecrosis of the jaws related to its use and how to manage these patients is extremely important. Therefore, in the current manuscript the authors aim to review the most important topics related to this pathological presentation. Key words:Bisphosphonates, alendronate, bisphosphonate-related osteonecrosis of the jaws, osteonecrosis.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Alendronate-associated osteonecrosis of the jaws: A review of the main topics

Fonseca

Santos‐Silva²,

Della-Coletta³

et al. 2014

Med Oral

View full text Add to dashboard Cite

show abstract

“…Khan et al recalled that this complication is rare and reported a cumulative incidence of 0.001% in Ontario for osteoporosis or metabolic bone disease observations 21 . This side effect is not always recognised by dentists 22 . De Lima et al found that 58% of Brazilian dentists did not recognise BP-related ONJ (BRONJ) as an oral side effect of BP or point out oral conditions that are not associated with the use of BP 23 .…”

Section: Discussionmentioning

confidence: 98%

“…recalled that this complication is rare and reported a cumulative incidence of 0.001% in Ontario for osteoporosis or metabolic bone disease observations. This side effect is not always recognised by dentists. De Lima et al .…”

Section: Discussionmentioning

confidence: 99%

Viewpoints of dentists on the use of bisphosphonates in rheumatology patients

Daron¹,

Soubrier²,

Mathieu³

2018

International Dental Journal

View full text Add to dashboard Cite

show abstract

“…• Lack and/or inadequate knowledge of BRONJ-related issues. A recent report (Lopez-Jornet et al, 2010) highlights that there are dental professionals who are not informed yet, or at least not adequately informed, as regards BRONJ and the management of patients taking bisphosphonates; of course, this is a breach of the duty of the prudent practitioner to remain current with scientific evidence.…”

mentioning

confidence: 99%